Escitalopram
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Escitalopram: From Major Depressive Disorder to Dysthymic Disorder
One-Sentence Summary
Escitalopram is a selective serotonin reuptake inhibitor (SSRI), originally used to treat depression (including major depressive disorder) and anxiety disorders. The TxGNN model's top-ranked prediction with real clinical support is Dysthymic Disorder (chronic low-grade depression), backed by 7 clinical trials and 6 publications (including a placebo-controlled RCT and a meta-analysis). Two other predictions also have meaningful support: Obsessive-Compulsive Disorder (12 trials, 20 publications) and Agoraphobia (1 trial, 16 publications).
Note: The highest-scoring prediction (Ohdo syndrome and variants, score 98.56%) has no trials or literature and is not considered credible. This report therefore focuses on the best-supported prediction, dysthymic disorder, and summarises the other candidates at the end.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Unipolar depression, endogenous depression, major depressive disorder, anxiety disorder (from the knowledge graph; approved indication text is not available in the Singapore licence records) |
| Predicted New Indication | Dysthymic disorder |
| TxGNN Prediction Score | 98.55% |
| Evidence Level | L1 (as assigned in the data compiled for this report; the evidence comes mostly from small studies, see below) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on known information, escitalopram is the active S-enantiomer of citalopram and belongs to the SSRI class. It blocks serotonin reuptake, and its efficacy in major depressive disorder and anxiety disorders is established.
Dysthymic disorder is a chronic, lower-grade depressive disorder in the same spectrum as major depressive disorder. A serotonergic mechanism is therefore mechanistically consistent with this use. A placebo-controlled randomised trial of escitalopram in dysthymia and a meta-analysis of antidepressants in dysthymia both support efficacy.
One caveat: the strongest design signals come from small studies (n=36 and n=40), not from a large Phase 3 programme. The L1 label reflects the mix of study types rather than multiple large pivotal trials.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00220701 | Phase 4 | Completed | 36 | 12-week double-blind placebo-controlled study of escitalopram in dysthymic disorder, with open-label extension |
| NCT00234312 | Phase 4 | Completed | 40 | Escitalopram vs. sertraline in dysthymic disorder and double depression |
| NCT00296712 | Phase 4 | Completed | 55 | Escitalopram/bupropion combination as first-line treatment for depression (combination design confounds the escitalopram effect) |
| NCT01973283 | Phase 4 | Completed | 100 | Antidepressant response in older adults with depressive symptoms and frailty |
| NCT00080158 | Phase 2/3 | Completed | 120 | Treatments for depressed adolescent suicide attempters (indirect relevance) |
| NCT00296777 | Phase 4 | Completed | 28 | Brain testing and fMRI as predictors of treatment outcome in depressed outpatients |
| NCT00404755 | Phase 4 | Completed | 17 | Dichotic listening as a predictor of medication response in depression |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21811192 | 2010 | RCT | Int Clin Psychopharmacol | 36 outpatients with dysthymic disorder randomised to escitalopram (up to 20 mg/day) or placebo for 12 weeks |
| 21527126 | 2011 | Meta-analysis | J Clin Psychiatry | Efficacy of antidepressants in dysthymia from placebo-controlled RCTs, compared with response in major depressive disorder |
| 19820552 | 2009 | RCT/Clinical study | J Psychiatr Pract | Whether starting with two antidepressants hastens and increases remission in depression |
| 25647343 | 2015 | Cohort | Psychoneuroendocrinology | Immune and cytokine changes (shift toward Th2 responses) in depressed patients treated with escitalopram |
| 21448115 | 2011 | Case/Cohort | Psychiatr Danub | Allergic reactions during sertraline and escitalopram treatment in a patient with dysthymia |
| 23260337 | 2013 | Case report/Review | Gen Hosp Psychiatry | SSRI-induced galactorrhea; 23 reported cases, mostly with escitalopram and paroxetine |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17140P | CILENTRA 10 (Escitalopram oxalate 10 mg) | Film-coated tablet | Not specified in licence record |
| SIN17139P | CILENTRA 20 (Escitalopram oxalate 20 mg) | Film-coated tablet | Not specified in licence record |
| SIN13780P | Lepax 10 mg | Coated tablet | Not specified in licence record |
| SIN12364P | LEXAPRO 15 mg | Film-coated tablet | Not specified in licence record |
| SIN12365P | LEXAPRO 5 mg | Film-coated tablet | Not specified in licence record |
Two further Lexapro licences (10 mg, SIN12363P; 20 mg, SIN12362P) are also valid, for 7 valid single-ingredient registrations in total.
Safety Considerations
- Disease contraindication signals (knowledge graph, not label text): epilepsy, bipolar disorder, major affective disorder, liver disease, gallbladder disease, blood coagulation disease, heart disease, cardiovascular disease, neuroleptic malignant syndrome, inappropriate ADH syndrome (including nephrogenic syndrome of inappropriate antidiuresis), and serotonin syndrome.
- Drug Interactions: 100 interactions were identified. Major-level examples include bupropion, lorcaserin, clarithromycin, diethylpropion, dolasetron, palonosetron and phentermine. Moderate-level examples include aspirin, cimetidine, omeprazole, morphine, famotidine, loperamide and glimepiride.
- Reported adverse effects in the literature: galactorrhea with SSRIs, including escitalopram (case reports).
Please refer to the package insert for the full warnings and contraindications, which were not available in the data compiled for this report.
Other Predicted Indications (Brief Summary)
| Predicted Indication | TxGNN Score | Evidence | Decision |
|---|---|---|---|
| Obsessive-compulsive disorder | 98.36% | L1; 12 trials (including Phase 3 and a randomised double-blind dose comparison, n=176) and a relapse-prevention RCT (PMID 17240120); escitalopram is a recognised SSRI option. Higher-than-labelled doses need dose, QTc and DDI guardrails | Proceed with Guardrails |
| Agoraphobia | 96.90% | L1 label, but stage S2; evidence is mainly for panic disorder with or without agoraphobia (placebo-controlled RCT, network meta-analyses). The single trial is a mindfulness vs. escitalopram study in anxiety disorders (n=276) | Proceed with Guardrails |
| Ohdo syndrome and variants; blepharophimosis-intellectual disability syndrome, Ohdo type; benign paroxysmal torticollis of infancy | 97.9–98.6% | L5; no trials or literature, no plausible mechanism | Hold |
| Paranoid, schizoid, histrionic and schizotypal personality disorders | 97.41% (identical) | L5; no trials. The identical scores suggest a class-level artefact of the model. The two retrieved papers do not address these disorders | Hold |
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Dysthymic disorder is closely related to the approved depression indications. A placebo-controlled RCT, a head-to-head trial against sertraline and a meta-analysis point in the same direction. However, the supporting studies are small, so the evidence is encouraging rather than conclusive.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (currently missing, and a blocking gap for safety screening)
- Mechanism-of-action data from DrugBank
- A larger, adequately powered trial or pooled analysis specific to escitalopram in dysthymia
- A DDI management plan, especially for major interactions (e.g., bupropion, clarithromycin, serotonergic agents), and attention to QTc risk
- Review of knowledge-graph contraindication signals (bipolar disorder, epilepsy, liver and cardiovascular disease, serotonin syndrome) against the label before patient selection
- Confirmation of the approved indication text for the Singapore licences, which is blank in the current records
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.